Kostandinos Sideras
Assistant Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
About
Kostandinos Sideras is an Assistant Professor at Mayo Clinic in the United States. His research primarily focuses on breast cancer, pancreatic cancer, and the immune microenvironment in various oncological contexts. Recent articles authored by Dr. Sideras include studies on the efficacy of pembrolizumab in triple-negative breast cancer and the impact of type I interferons on pancreatic malignancies.
Articles (24)
Purpose: Activation of the RAS/MAPK pathway is associated with reduced tumor-infiltrating lymphocytes and poor outcomes in triple-negative breast cancer. Previous studies demonstrated that inhibition of the MAPK pathway with a MEK inhibitor is synergistic with immune checkpoint inhibitors. Patients and Methods: We conducted a phase I/II trial of pembrolizumab and binimetinib in patients with metastatic triple-negative breast cancer with ≤3 prior lines of therapy. There were two dose levels (DL) with binimetinib at 45 mg at DL 0 and 30 mg at DL −1. Results: The recommended phase II dose was the standard dose of pembrolizumab with binimetinib 30 mg twice daily. The objective response rate (ORR) was 30.4%, with a numerically higher ORR in patients without liver metastasis at 45.5%. Among patients who achieved objective responses, 80% had a duration of response >12 months and ongoing even after stopping treatment (5.4–69.0 months). Patients with PD-L1–positive tumors (modified proportion score ≥10) were more likely to respond with an ORR of 66.7%. However, clinical benefit was observed in 25% of patients with PD-L1–negative tumors. Consistent with preclinical studies, four of six patients with clinical benefit had either increased PD-L1 or decreased p-ERK expressions in serial circulating cancer-associated macrophage-like cells after starting binimetinib. Conclusions: Pembrolizumab and binimetinib at 30 mg are safe with manageable toxicities. Promising activity was observed in patients without liver metastases. Future larger clinical trials are warranted to further evaluate the efficacy of this chemotherapy-free combination.
Year:
2025
Supplementary Table 9. Median overall survival (OS) and hazard ratios for the CTC change groups as categorized based on the ≥5 CTC cutoff for CTC positivity (reference group neg/neg) for patients that received chemotherapy-based or endocrine therapy-based treatment.
Year:
2025
Supplementary Table 3: Comparisons of the probabilities of being CTC positive among tumor subtypes (hormone receptor-positive/HER2-negative, HER2-positive, triple-negative) according to time point of CTC assessment (baseline, first follow-up) and cutoff for CTC positivity (≥1 CTC, ≥5 CTCs). Probabilities of being CTC positive are given in terms of percentages and odds ratios with 95% confidence intervals (CI) obtained using binary logistic regression models with the response variable CTC positive (yes vs no)
Year:
2025
Supplementary Table 7. Median overall survival (OS) and hazard ratios for the CTC change groups as categorized based on the ≥5 CTC cutoff for CTC positivity (reference group neg/neg) for patients with hormone receptor-positive/HER2-negative, HER2-positive and triple-negative tumors.
Year:
2025
Supplementary Table 4: Comparisons of the probabilities of being CTC positive betweenHER2- positive/hormone receptor-positive and HER2-positive/hormone receptor-negative tumors according to time point of CTC assessment (baseline, first follow-up) and cutoff for CTC positivity (≥1 CTC, ≥5 CTCs). Probabilities of being CTC positive are given in terms of percentages and odds ratios with 95% confidence intervals (CI) obtained using binary logistic regression models with the response variable CTC positive (yes vs no).
Year:
2025
Supplementary Figure 4. Kaplan-Meier plot of overall survival according to change in CTC status from baseline to first follow-up (cutoff for CTC positivity ≥1 CTC). (A) HER2-positive/hormone receptor-positive tumors; (B) HER2-positive/hormone receptor-negative tumors. Survival time is given as time since baseline CTC assessment in months. The P-values refers to the global log rank test with 3 degrees of freedom.
Year:
2025
Supplementary Figure 3: Kaplan-Meier plots of overall survival (OS) according to CTC status at baseline for HER2-positive/hormone receptor-positive tumors(A, B) and HER2-positive/hormone receptor-negative tumors(C, D). Survival time is given as time since baseline CTC assessment in months. (A, C) cutoff for CTC positivity ≥1 CTC; (B, D) cutoff for CTC positivity ≥5 CTCs. The P-values refer to pairwise comparisons with the log rank test.
Year:
2025
Supplementary Figure 2: Kaplan-Meier plots of overall survival (OS) according to CTC status at baseline for a cutoff for CTC positivity ≥1 CTC (A, B, C) and a cutoff for CTC positivity ≥5 CTCs (D, E, F). Survival time is given as time since baseline CTC assessment in months. (A, D) hormone receptor-positive/HER2-negative tumors; (B, E) HER2- positive tumors; (C, F) triple-negative tumors. The P-values refer to pairwise comparisons with the log rank test.
Year:
2025
Supplementary Table 2. Absolute and relative frequencies of CTC change groups and percentage of CTC responders (as categorized according to the ≥1 CTC or ≥5 CTC cutoff for CTC positivity) overall, according to tumor subtypes and according to treatment type.
Year:
2025
Supplementary Table 5: Comparisons of the probabilities of patients that are CTC positive at baseline being a CTC responder (i.e., switching from CTC positive at baseline to CTC negative at first follow-up) among tumor subtypes (hormone receptor-positive/HER2-negative, HER2-positive, triple-negative) according to cutoff for CTC positivity (≥1 CTC, ≥5 CTCs). Probabilities of being a CTC responder are given in terms of percentages and odds ratios with 95% confidence intervals (CI) obtained using binary logistic regression models with the response variable CTC responder (yes vs no).
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2022
Year:
2021
Year:
2021
Year:
2020
Year:
2020
Year:
2020
Year:
2020
Collaborators (28)
Keith Knutson
Mayo Clinic Florida
Catherine Alix-Panabières
Director/Professor
University Hospital of Montpellier
Paola Gazzaniga
Sapienza University of Rome
Daniel F. Hayes
Stuart B. Padnos Professor of Breast Cancer Research
University of Michigan Rogel Cancer Center
Michail Ignatiadis
Leader Investigator Initiated Trials
Institut Jules Bordet
Lisa Anne Carey
Deputy Director for Clinical Science
University of North Carolina at Chapel Hill
Zeruesenay Desta
Professor of Medicine
Indiana University
Siddhartha Yadav
Associate Professor of Oncology
Mayo Clinic
Francois-Clement Bidard
Professor of Medical Oncology
Institut Curie
Hope Rugo
Director, Women’s Cancer Program Division; Professor, Department of Medical Oncology & Therapeutics Research; Chief, Breast Medical Oncology
City Of Hope National Medical Center
Matthew Goetz
Professor of Oncology and Pharmacology
Mayo Clinic
Jean-Yves Pierga
Head of Department
Institut Curie
Karthik Giridhar
Assistant Professor
Mayo Clinic
Tanja Fehm
Professor
University Hospital Düsseldorf
Carlos Caldas
Professor
Hebrew University of Jerusalem
Ravinder Singh
Professor
Mayo Clinic
Leon W. M. M. Terstappen
University of Twente
Elisabetta Munzone
Director
European Institute of Oncology
Justin Stebbing
Professor
Imperial College London
Evi Lianidou
PROFESSOR
National and Kapodistrian University of Athens
James Ingle
Mayo Clinic Rochester
Minetta Liu
Research Collaborator, Professor
Mayo Clinic
Saranya Chumsri
Professor of Oncology
Mayo Clinic Florida
Massimo Cristofanilli
Professor of Medicine
Weill Cornell Medicine
Kathryn Ruddy
Professor
Mayo Clinic
Klaus Pantel
-
Markus Wallwiener
University Hospital Heidelberg
DANIELE GENERALI
University of Trieste
Make your next move.
Prepare your application
Review drafts before you send them.